Browsing Tag
Merit Cudkowicz
2 posts
NeuroSense Therapeutics (NASDAQ: NRSN) advances PrimeC development after JAMA Neurology publishes PARADIGM Phase 2b ALS trial results
JAMA Neurology publishes PARADIGM trial results showing PrimeC slowed ALS decline. Discover what this means for NeuroSense Therapeutics’ Phase 3 plans.
Neurizon Therapeutics (ASX: NUZ) just crossed the threshold every ALS biotech dreams about. Now the hard part starts.
Neurizon Therapeutics (ASX: NUZ) doses first ALS patient in the HEALEY Platform Trial. What the Phase 2/3 design means for investors and the sector. Read more.